Saltar al contenido
Merck

PhotoPROTACs: A Novel Biotechnology for Cancer Treatment.

Trends in cell biology (2020-08-29)
Zhi-Wei Wang, Yi Liu, Xueqiong Zhu
RESUMEN

PROteolysis-TArgeting Chimeras (PROTACs) have been developed for targeting specific protein destruction. Two recent studies in Science Advances by Liu et al. and Reynders et al. reported a novel technology, PHOtochemically TArgeting Chimeras (PHOTACs) or opto-PROTAC, which is light-induced control of protein degradation. This new approach might lead to precision therapeutics in patients with cancer.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Lenalidomide-Photoswitch2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Lenalidomide-Photoswitch1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Thalidomide-Photoswitch3-NH2 hydrochloride, ≥95%